Naths Grazia Sukubo

Dr. Naths Grazia Sukubo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in International Journal of Surgery
Verified
Journal Article
Closed access
NSNaths Grazia Sukubo
Naths Grazia Sukubo
ETElisabetta Tibalt
Elisabetta Tibalt
SRStefano Respizzi
Stefano Respizzi
MLMassimo Locati
Massimo Locati
MDM.Cristina D'Agostino
M.Cristina D'Agostino
Extracorporeal Shock Wave Therapy (ESWT) is broadly used as a non-surgical therapy in various diseases for its pro-angiogenic and anti-inflammatory effects. However, the molecular mechanisms translating tissue exposure to shock waves (SW) in a biological response with potential therapeutic activity are largely unknown. As macrophages take part in both the onset and amplification of the inflammatory response, and well in its resolution, we investigated the effect of SW on their biology. Human monocyte-derived macrophages were polarized to classic (M1) pro-inflammatory macrophages or alternative (M2) anti-inflammatory macrophages and exposed to SW ad different intensities. Expression levels of marker genes of macrophage activation were measured by qPCR at different time points. SW did not induce activation of resting macrophages at any energy level used. Conversely, when used at low energy SW caused a significant inhibition of some M1 marker genes (CD80, COX2, CCL5) in M1 macrophages and a significant synergistic effect for some M2 marker genes (ALOX15, MRC1, CCL18) in M2 macrophages. SW also affected cytokine and chemokine production, inducing in particular a significant increase in IL-10 and reduction in IL-1β production. Macrophage exposure to low energy SW dampens the induction of the pro-inflammatory profile characterizing M1 macrophages and promotes the acquisition of an anti-inflammatory profile synergizing with macrophage alternative activation.

14 February 2025 in Advanced Science
Verified
Journal Article
Open access
JAJennifer Fernandez Alarcon
Jennifer Fernandez Alarcon
PSPatricia Perez Schmidt
Patricia Perez Schmidt
NPNicolo Panini
Nicolo Panini
FCFrancesca Caruso
Francesca Caruso
MVMartina Bruna Violatto
Martina Bruna Violatto
GSGiovanni Sitia
Giovanni Sitia
Macrophages are crucial drivers of innate immunity. Reprogramming macrophages to a restorative phenotype in cancer or autoimmune diseases can stop their cancer‐promoting activity or trigger anti‐inflammatory immunity. Glycans have emerged as key components for immunity as they are involved in many pathophysiological disorders. Previous studies have demonstrated that supraphysiological amounts of mannose (Man) or sialic acid (Sia) can inhibit tumor growth and stimulate differentiation of regulatory T cells. Man is known to affect glucose metabolism in glycolysis by competing for the same intracellular transporters and affecting macrophage polarization, whereas Sia alters macrophage differentiation via signaling through Siglec‐1. Herein, this work describes a macrophage targeting platform using gold nanoparticles (GNPs) functionalized with Man and Sia monosaccharides which exhibit high liver tropism. A single dose of glyco‐GNPs can convert macrophages to a restorative phenotype in two completely different immune environments. Man promotes tumor‐associated macrophages toward an antitumorigenic activity in a MC38 liver colorectal cancer model by secretion of TNF‐α, IL ‐1β, and IL ‐6 in the tumor microenvironment. However, in a proinflammatory environment, as observed in a mouse model of autoimmune disease, primary biliary cholangitis, Man impairs the production of TNF‐α, IL‐1β, Arg1, and IL‐6 cytokines. The results probe the dual role of Man in macrophage repolarization in response to the immune system. This study is a proof‐of‐concept that demonstrates that nanomedicine using specific glycans designed to target other immune cells such as myeloid cells, are a promising strategy not only against cancer but also against other pathologies such as autoimmune diseases.

31 January 2025 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
NSNaths Grazia Sukubo
Naths Grazia Sukubo
Paolo BiginiPaolo Bigini
Paolo Bigini
AMAnnalisa Morelli
Annalisa Morelli
In the coming decades, the development of nanocarriers (NCs) for targeted drug delivery will mark a significant advance in the field of pharmacology. NCs can improve drug solubility, ensure precise distribution, and enable passage across biological barriers. Despite these potential advantages, the interaction with many biological matrices, particularly with existing macrophages, must be considered. In this review, we will explore the dual role of macrophages in NC delivery, highlighting their physiological functions, the challenges posed by the mononuclear phagocyte system, and innovative strategies to exploit macrophage interactions for therapeutic advantage. Recent advancements in treating liver and lung diseases, particularly focusing on macrophage polarization and RNA-based therapies, have highlighted the potential developments in macrophage–NC interaction. Furthermore, we will delve into the intriguing potential of nanomedicine in neurology and traumatology, associated with macrophage interaction, and the exciting possibilities it holds for the future.

27 January 2026 in Gut
Verified
Journal Article
Closed access
NSNaths Grazia Sukubo
Naths Grazia Sukubo
CCChiara Caime
Chiara Caime
AGAlessio Gerussi
Alessio Gerussi
PIPietro Invernizzi
Pietro Invernizzi

15 September 2026 in Small
Verified
Journal Article
Open access
PDF file
NSNaths Grazia Sukubo
Naths Grazia Sukubo
SRSerena Renzi
Serena Renzi
MVMartina Bruna Violatto
Martina Bruna Violatto
LALeila Altigieri
Leila Altigieri
ACAnna Laura Capriotti
Anna Laura Capriotti
Giulio CaraccioloGiulio Caracciolo
Giulio Caracciolo
Lipid nanoparticles (LNPs) preferentially accumulate in the liver, but hepatic tropism alone does not ensure productive RNA interference. Here, we screened a library of LNPs in which lipid composition was varied to generate distinct protein corona identities and identify formulations capable of combining liver accumulation with functional siRNA delivery. LNP1 emerged as the lead formulation, showing favorable physicochemical properties, high transfection efficiency, and enhanced hepatic accumulation. Proteomic analysis associated this behavior with a distinct multicomponent corona signature. When loaded with siRNA targeting tissue inhibitor of metalloproteinases 1 (TIMP1), a key regulator of extracellular matrix turnover and fibrosis, LNP1 was efficiently internalized by primary Kupffer cells (KCs) and induced robust target knockdown. Consistent with this cellular preference, quartz crystal microbalance measurements showed that corona formation increased LNP1 binding to MARCO, a scavenger receptor expressed by KCs. In a mouse model of primary biliary cholangitis, repeated administration of siTIMP1‐loaded LNP1 reduced TIMP1 expression in KCs, reactivated extracellular‐matrix‐degradative pathways, suppressed pro‐inflammatory signaling and macrophage infiltration, alleviated cholestasis and attenuated liver fibrosis. These findings connect systematic variation in lipid composition with corona identity, hepatic tropism, and functional gene silencing, supporting protein corona engineering as a strategy to bridge liver accumulation with productive siRNA delivery.

22 July 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MVMartina Bruna Violatto
Martina Bruna Violatto
MVManuela Vitulo
Manuela Vitulo
ESElisa Schiavon
Elisa Schiavon
CCChiara Caime
Chiara Caime
AMAnnalisa Morelli
Annalisa Morelli
DBDonatella Barisani
Donatella Barisani
Primary biliary cholangitis (PBC) is the most common life-long autoimmune liver disease arising from a biliary epithelial activation to a complex evolving cascade of immune-mediated injury, leading to inflammation and fibrosis and ultimately cirrhosis and liver failure. Ursodeoxycholic acid (UDCA) remains the only first-line treatment, despite being ineffective in approximately 40% of patients. Inadequate response to UDCA has been associated with increased death risk or need for liver transplantation. Starting from these premises, novel or repurposed drugs are currently needed. Immunosuppressive therapies, such as corticosteroids, remain controversial, primarily due to safety concerns related to off-target effects and limited evidence of enhanced efficacy. Nanoparticles are known to accumulate in the liver. Among them, Avidin-Nucleic-Acids-Nano-ASsemblies (ANANAS) have emerged as promising drug carriers thanks to their multi-functionality and convenient tunability, biodegradability, biocompatibility and scalable manufacturing. Despite the availability of numerous PBC models, none replicate key features of human disease to the degree observed in ARE Del-/- mice. Focusing on this model, ANANAS loaded with acid-releasable dexamethasone (ANANAS-Hz-Dex-M) were parenterally administered to evaluate distribution, pharmacokinetics, and therapeutic efficacy. The single treatment demonstrated selective liver tropism with an exclusive steroid release, and interaction with resident macrophages. Multiple administrations significantly reduced hepatic fibrosis. In vitro, isolated Kupffer cells from ARE Del-/- internalize the nanoassembly, with a reduction of the inflammatory profile. Our findings delineate ANANAS-Hz-Dex-M as a tool with the potential to guide resident macrophage plasticity and ameliorate disease course.